Wonky US Health Policy Communications Creates Investor Opportunities
Investors who know where to look can profit
This article is for subscribers only.
Welcome back to Bloomberg’s Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the future of medicine. Sign up now if you’re not already on the list.
There’s good news on the cancer front. Revolution Medicine’s pancreatic cancer pill nearly doubled survival rates for one of the hardest-to-treat tumor types and GSK is returning to oncology with a full slate of trials for its promising Mo-Rez compound.